top of page
Get in touch
NEWS
Press releases & papers
3/4/25
Press release
remynd strenghtens drug development focus with strategic sale of CRO business to InnoSer
3/7/24
Press release
remynd announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease
9/3/24
Press release
remynd appoints new CEO and Chairman to progress novel Alzheimer’s Disease program through clinical development
bottom of page